118 related articles for article (PubMed ID: 33140463)
1. Evaluation of the oral administration of α-l-guluronic acid on COX-1 and COX-2 gene expression profile in ankylosing spondylitis patients.
Sadoughi A; Mansouri R; Nazeri S; Mirshafiey A
Drug Dev Res; 2021 Apr; 82(2):296-301. PubMed ID: 33140463
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the Effect of α-L-Guluronic Acid (G2013) on COX-1, COX-2 Activity and Gene Expression for Introducing this Drug as a Novel NSAID with Immunomodulatory Property.
Mirshafiey A; Mortazavi-Jahromi SS; Taeb M; Cuzzocrea S; Esposito E
Recent Pat Inflamm Allergy Drug Discov; 2018; 12(2):162-168. PubMed ID: 29879894
[TBL] [Abstract][Full Text] [Related]
3. Assessment of immunological profile in ankylosing spondylitis patients following a clinical trial with guluronic acid (G2013), as a new NSAID with immunomodulatory properties.
Mortazavi-Jahromi SS; Nazeri S; Jafarnezhad-Ansariha F; Oraei M; Mirshafiey A
Immunol Res; 2019 Feb; 67(1):108-115. PubMed ID: 30474833
[TBL] [Abstract][Full Text] [Related]
4. The effects of β-D-mannuronic acid (M2000), as a novel NSAID, on COX1 and COX2 activities and gene expression in ankylosing spondylitis patients and the murine monocyte/macrophage, J774 cell line.
Jafarnezhad-Ansariha F; Yekaninejad MS; Jamshidi AR; Mansouri R; Vojdanian M; Mahmoudi M; Fattahi MJ; Hashemi SN; Rehm BHA; Matsuo H; Esposito E; Cuzzocrea S; Mirshafiey A
Inflammopharmacology; 2018 Apr; 26(2):375-384. PubMed ID: 28819782
[TBL] [Abstract][Full Text] [Related]
5. Pivotal cytokines and their transcription factors are the targets of guluronic acid (G2013) for inhibiting the immunopathogenesis process of multiple sclerosis.
Hossein-Khannazer N; Shabani S; Farokhfar M; Azizi G; Asarzadegan F; Safarpour Lima B; Mirshafeiey A
Drug Dev Res; 2020 Jun; 81(4):511-516. PubMed ID: 32103523
[TBL] [Abstract][Full Text] [Related]
6. The safety and efficacy of Guluronic acid (G2013) in ankylosing spondylitis: A randomized controlled parallel clinical trial.
Nazeri S; Jamshidi AR; Mahmoudi M; Vojdanian M; Khadem Azarian S; Afraei S; Mostafaei S; Hosseini M; Mirshafiey A
Pharmacol Rep; 2019 Jun; 71(3):393-398. PubMed ID: 31003148
[TBL] [Abstract][Full Text] [Related]
7. Effect of Guluronic Acid (G2013), As a New Anti-inflammatory Drug on Gene Expression of Pro-inflammatory and Anti-inflammatory Cytokines and Their Transcription Factors in Rheumatoid Arthritis Patients.
Bakhtiari T; Azarian S; Ghaderi A; Ahmadzadeh A; Mirshafiey A
Iran J Allergy Asthma Immunol; 2019 Nov; 18(6):639-648. PubMed ID: 32245307
[TBL] [Abstract][Full Text] [Related]
8. The effects of guluronic acid (G2013), a new emerging treatment, on inflammatory factors in nonalcoholic steatohepatitis patients under
Tahmasebi S; Neishaboori H; Jafari D; Faghihzadeh E; Esmaeilzadeh A; Mirshafiey A
Immunopharmacol Immunotoxicol; 2021 Oct; 43(5):562-570. PubMed ID: 34314306
[TBL] [Abstract][Full Text] [Related]
9. Immunomodulatory Effect of G2013 (α-L-Guluronic Acid) on the TLR2 and TLR4 in Human Mononuclear Cells.
Sharifi L; Mohsenzadegan M; Aghamohammadi A; Rezaei N; Zavareh FT; Bokaie S; Moshiri M; Aghazadeh Z; Norouzbabaie Z; Azizi G; Mirshafiey A
Curr Drug Discov Technol; 2018; 15(2):123-131. PubMed ID: 28578651
[TBL] [Abstract][Full Text] [Related]
10. Effects of guluronic acid, as a new NSAID with immunomodulatory properties on IL-17, RORγt, IL-4 and GATA-3 gene expression in rheumatoid arthritis patients.
Khadem Azarian S; Jafarnezhad-Ansariha F; Nazeri S; Azizi G; Aghazadeh Z; Hosseinzadeh E; Mirshafiey A
Immunopharmacol Immunotoxicol; 2020 Feb; 42(1):22-27. PubMed ID: 31856612
[No Abstract] [Full Text] [Related]
11. An in vitro evaluation of anti-aging effect of guluronic acid (G2013) based on enzymatic oxidative stress gene expression using healthy individuals PBMCs.
Taeb M; Mortazavi-Jahromi SS; Jafarzadeh A; Mirzaei MR; Mirshafiey A
Biomed Pharmacother; 2017 Jun; 90():262-267. PubMed ID: 28364598
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of G2013 (α-L-guluronic acid) efficacy on PC-3 cells through inhibiting the expression of inflammatory factors.
Bagherian Z; Mirshafiey A; Mohsenzadegan M; Farajollahi MM
Clin Exp Pharmacol Physiol; 2022 Feb; 49(2):254-263. PubMed ID: 34699087
[TBL] [Abstract][Full Text] [Related]
13. The Immunomodulatory Role of G2013 (α-L-Guluronic Acid) on the Expression of TLR2 and TLR4 in HT29 cell line.
Farhang H; Sharifi L; Dallal MMS; Moshiri M; Norouzbabaie Z; Bokaie S; Aletaha S; Zargar SJ; Mirshafiey A
Curr Drug Discov Technol; 2019; 16(1):91-95. PubMed ID: 29484999
[TBL] [Abstract][Full Text] [Related]
14. Oral administration effects of β-d-mannuronic acid (M2000) on Th17 and regulatory T cells in patients with ankylosing spondylitis.
Fattahi MJ; Ahmadi H; Jafarnezhad-Ansariha F; Mortazavi-Jahromi SS; Rehm BHA; Cuzzocrea S; Matsuo H; Mirshafiey A
Biomed Pharmacother; 2018 Apr; 100():495-500. PubMed ID: 29477913
[TBL] [Abstract][Full Text] [Related]
15. The Evaluation of Safety Property and Apoptotic Efficacy of α-L-Guluronic Acid (G2013), as a Novel NSAID, Under
Hassani S; Afshari JT; Jafarnezhad-Ansariha F; Mirshafiey A
Recent Adv Inflamm Allergy Drug Discov; 2022; 15(1):9-15. PubMed ID: 34503439
[TBL] [Abstract][Full Text] [Related]
16. Anti-Diabetic and Angio-Protective Effect of Guluronic Acid (G2013) as a New Nonsteroidal Anti-Inflammatory Drug in the Experimental Model of Diabetes.
Mortazavi-Jahromi SS; Alizadeh S; Javanbakht MH; Mirshafiey A
Endocr Metab Immune Disord Drug Targets; 2020; 20(3):446-452. PubMed ID: 31622213
[TBL] [Abstract][Full Text] [Related]
17. Influence of CYP2C9 and COX-2 Genetic Polymorphisms on Clinical Efficacy of Non-Steroidal Anti-Inflammatory Drugs in Treatment of Ankylosing Spondylitis.
Wang Y; Yi XD; Lu HL
Med Sci Monit; 2017 Apr; 23():1775-1782. PubMed ID: 28403136
[TBL] [Abstract][Full Text] [Related]
18. Kunxian capsules in the treatment of patients with ankylosing spondylitis: a randomized placebo-controlled clinical trial.
Li Q; Li L; Bi L; Xiao C; Lin Z; Cao S; Liao Z; Gu J
Trials; 2016 Jul; 17(1):337. PubMed ID: 27449221
[TBL] [Abstract][Full Text] [Related]
19. The Open, Randomized, Positive Control Clinical Trial of Guluronic Acid (G2013) on SARS-CoV-2 Patients.
Aghazadeh Z; Sanaee Delir D; Gholamrezaie HR; Sadoughi A; Nezami Asl A; Noori Sanami M; Mahdavi Gorabi A; Panahi Y; Taeb M; Razavi A; Rafia S; Naderiyan Z; Robat-Jazi B; Mirshafiey A
Curr Drug Discov Technol; 2023; 20(4):e180423215957. PubMed ID: 37076459
[TBL] [Abstract][Full Text] [Related]
20. Effects of guluronic acid (G2013) on gene expression of TLR2, TLR4, MyD88, TNF-α and CD52 in multiple sclerosis under in vitro conditions.
Noorbakhsh SM; Razavi A; Moghadam NB; Saadat P; Hoseini M; Aghazadeh Z; Mobini M; Oraei M; Mirshafiey A
Immunopharmacol Immunotoxicol; 2019 Dec; 41(6):586-590. PubMed ID: 31594427
[No Abstract] [Full Text] [Related]
[Next] [New Search]
